Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung Cancer

• Үндсэн зохиолчид: Xiaomin Wan (Зохиогч), Xiaohui Zeng (Зохиогч), Liubao Peng (Зохиогч), Ye Peng (Зохиогч), Qiao Liu (Зохиогч), Lidan Yi (Зохиогч), Xia Luo (Зохиогч), Qijian Deng (Зохиогч), Chongqing Tan (Зохиогч)
• Формат: Ном
• Хэвлэсэн: Frontiers Media S.A., 2021-08-01T00:00:00Z.
• Нөхцлүүд: article
• Онлайн хандалт: Connect to this object online.

Objective: This study evaluated the cost-effectiveness of nivolumab plus ipilimumab vs. chemotherapy in the first-line setting for patients with advanced non-small-cell lung cancer (NSCLC) from the US payer perspective.Materials and methods: A Markov model wasdeveloped to evaluate the cost and effec...